重组人脑利钠肽早期治疗高龄老年射血分数保留的心力衰竭临床分析

Recombinant Human Brain Natriuretic Peptide in Early Treatment of Heart Failure with Preserved Ejection Fraction in the Elderly

目的探究重组人脑利钠肽早期治疗高龄老年射血分数保留的心力衰竭临床疗效。方法便利择取2018年1月—2019年12月期间该院收治的120例高龄老年射血分数保留心衰患者参与研究,根据抽签法进行随机分组,包括对照组60例和观察组60例。对照组患者行常规疗法,观察组患者行早期重组人脑利钠肽治疗,比较两组患者24 h尿量、NT-proBNP水平、卧床时间、住院时间、临床疗效和不良反应发生率。结果观察组患者24 h尿量(1568.25±163.45)mL、NT-proBNP水平(5214.32±50.68)pg/mL、卧床时间(8.62±1.48)d、住院时间(15.26±2.14)d优于对照组(1234.42±154.13)mL、(8762.54±65.47)pg/mL、(10.75±1.35)d、(18.47±2.62)d,差异有统计学意义(t=11.510、331.963、8.236、7.750,P<0.05);观察组患者临床疗效率95.00%高于对照组81.67%,差异有统计学意义(χ^(2)=5.175,P<0.05);观察组患者不良反应发生6.67%低于对照组10.00%,但差异无统计学意义(χ^(2)=0.436,P>0.05)。结论高龄老年射血分数保留心衰患者早期开展重组人脑利钠肽治疗可有效改善其病情,对改善患者预后具有重要意义,因此该种治疗方法值得在临床中进行推广应用。

Objective To explore the clinical efficacy of recombinant human brain natriuretic peptide in the early treatment of heart failure with preserved ejection fraction in the elderly.Methods From January 2018 to December 2019,120 elderly patients with heart failure with preserved ejection fraction treated in the hospital were conveniently selected to participate in the study,and randomized according to the lottery method,including 60 cases in the control group and 60 cases in the observation group.Patients in the control group received conventional therapy,and patients in the observation group received early recombinant human brain natriuretic peptide treatment.The 24 h urine output,NT-proBNP level,bed time,hospital stay,clinical efficacy and incidence of adverse reactions were compared between the two groups.Results The 24 h urine output(1568.25±163.45)mL,NT-proBNP level(5214.32±50.68)pg/mL,bed time(8.62±1.48)d,and hospitalization time(15.26±2.14)d of patients in the observation group were better than those in the control group(1234.42±154.13)mL,(8762.54±65.47)pg/mL,(10.75±1.35)d,(18.47±2.62)d,the difference was statistically significant(t=11.510,331.963,8.236,7.750,P<0.05);the clinical treatment efficiency of the observation group was 95.00%,which was higher than that of the control group 81.67%,the difference was statistically significant(χ^(2)=5.175,P<0.05);adverse reactions in the observation group were 6.67%,which was lower than 10.00%in the control group,but the difference was not statistically significant(χ^(2)=0.436,P>0.05).Conclusion Early treatment with recombinant human brain natriuretic peptide in elderly patients with heart failure with preserved ejection fraction can effectively improve their condition and is of great significance to improve the prognosis of patients.Therefore,this treatment method is worthy of clinical application.